SomnusNooze e-newsletter
News, stories and updates from the world of sleep
SomnusNooze topics: Idiopathic hypersomnia
Hypersomnia Research-Where We Are and Where We Are Headed
During the presentation by David Rye, MD, PhD, titled “What are the latest developments in research on idiopathic hypersomnia?” at the Beyond Sleepy in the Mile-High City Hypersomnia Conference, he pointed out that, while on the one hand without a... read >
Act Today and Let Your Voice Be Heard
Very recently, the Hypersomnia Foundation became aware of an opportunity to help shape the future of sleep research. The National Institutes of Health, the primary source of funding for medical research in the United States, has issued a Request... read >
Sleep-Wake Disturbance Following a Traumatic Brain Injury
Background According to the Centers for Disease Control and Prevention (CDC), more than 2 million people in the United States suffer a traumatic brain injury (TBI) every year. Most people with a TBI will also experience a sleep-wake disturbance... read >
What Does One SOREMP Mean?
Background The primary feature of the two main central disorders of hypersomnolence—narcolepsy and idiopathic hypersomnia (IH)—is excessive daytime sleepiness, defined in the International Classification of Sleep Disorders, third edition,... read >
A Comparison of Sodium Oxybate in the Treatment of Idiopathic Hypersomnia and Narcolepsy Type 1
Background Sodium oxybate (SXB) is a drug sold as Xyrem in the United States by Jazz Pharmaceuticals, in Europe by UCB Pharma, and in Canada by Valeant Pharmaceuticals. It is approved in the United States in adults for the treatment of excessive daytime... read >
Does Excessive Daytime Sleepiness Affect Children’s Pedestrian Safety?
Background Each year, approximately 30,000 children are unintentionally killed or injured while walking outside (typically within a half mile of their homes). Many factors—including children’s thinking and reasoning abilities, attention spans,... read >
The Hypersomnia Foundation Welcomes New Board Members
We are pleased to announce that Scot Hulshizer, Celia King, and Diane Powell have recently been elected to the Board of Directors of the Hypersomnia Foundation. In addition to bringing unique strengths as the organization thrives and grows in both scope... read >
Raising Awareness of the Underpinnings of Hypersomnia
Awareness of disease means different things to different people. One’s awareness takes origin in experiences and goals, both personal and professional. Diversity in awareness therefore comprises our community of people who have hypersomnia, their... read >
Antibiotic May Decrease EDS in GABA-Related Hypersomnia
A study of clarithromycin in the treatment of GABA-related hypersomnia indicates that this drug may be effective in some patients with idiopathic hypersomnia (IH), narcolepsy without cataplexy, and subjective hypersomnia. Background The US Food and... read >
It’s a Fine Line Between Type 2 Narcolepsy and Idiopathic Hypersomnia… and It’s Getting Even Finer
Researchers have provided more evidence that narcolepsy without cataplexy (Nw/oC ) and idiopathic hypersomnia (IH) without long sleep time (LST) look more alike on testing than do narcolepsy with cataplexy (NwC) and Nw/oC. This research was completed... read >